+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Raji cells using CD1B mouse mAb (green) and negative control (red).    

  
  

CD1b antibodies target the CD1b protein, a member of the CD1 family of antigen-presenting molecules. Unlike classical MHC molecules that present peptide antigens, CD1b specializes in binding and presenting lipid-based antigens to specific T cells, particularly natural killer T (NKT) cells and γδ T cells. This unique function enables the immune system to detect lipid components from pathogens like Mycobacterium tuberculosis, which have lipid-rich cell walls. CD1b is primarily expressed on antigen-presenting cells, such as dendritic cells and B cells, and plays a critical role in bridging innate and adaptive immunity.

Research on CD1b antibodies has focused on their diagnostic and therapeutic potential. In diagnostics, these antibodies help detect CD1b expression in tissues, aiding studies of immune responses to lipid antigens or CD1b dysregulation in diseases. Therapeutically, CD1b-targeting strategies are explored for infectious diseases (e.g., tuberculosis) and cancers, where CD1b overexpression in malignancies like melanoma or lymphoma may contribute to immune evasion. Additionally, CD1b antibodies are tools for elucidating lipid antigen presentation mechanisms and developing lipid-based vaccines. Despite progress, challenges remain in understanding CD1b’s ligand diversity and tissue-specific roles, driving ongoing studies to harness its immunological functions for clinical applications.